Proteinases in the joint: clinical relevance of proteinases in joint destruction

Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis.

OBJECTIVE We previously described abnormalities in the bone marrow of patients with rheumatoid arthritis (RA), but were able to shed little light on the pathogenic roles of inflammatory cytokines and proteinases in joint destruction in the subchondral region in RA. This is the first report to describe the co-localization of cytokines and proteinases in this area. METHODS Decalcified paraffin-...

بررسی همراهی اروزیون مفصلی با یافته های بالینی و آزمایشگاهی در آرتریت روماتوئید

Introduction & Objective: Rheumatoid Arthritis (RA) is a chronic progressive inflammatory disease of the articular joint that results in significant pain, stiffness and swelling and leads to destruction. The clinical findings and biomarkers application can allow clinicians to quality the effects of aggressive treatment during the first stage of the disease in order to prevent joint destructio...

Bivalent DNA Vaccination with Genes Encoding Leishmania major Cysteine Proteinases Type I and II Protects Mice Against Infectious Challenge

Diverse expression of selected cytokines and proteinases in synovial fluid obtained from osteoarthritic and healthy human knee joints

BACKGROUND Osteoarthritis (OA) is defined by signs and symptoms of inflammation within the affected joint. The aim of this study is to determine the mRNA expression levels of selected cytokines and matrix-metalloproteinases of cells found in synovial fluid (SF) obtained from osteoarthritic knee joints compared to healthy controls. METHODS SF was obtained from 40 patients undergoing total knee...

Perioperative Surgical Site Infections and Complications in Elective Orthopedic Surgery in Patients with Rheumatoid Arthritis Treated with Anti-Tumor Necrosis Factor-Alpha Agents − Discontinue or Not, Clinical Dilemma

Most patients with RA are in use of traditional disease modifying antirheumatic drugs (DMARDs) to control disease activity, and among the traditional, non-biological DMARDs (nbDMARDs), methotrexate (MTX) is a first line and an anchor drug for the treatment of RA. Currently introduced biologic agents, especially anti-tumor necrosis factor-alpha (TNFα) agents, have revolutionized the treatment of...